Crizotinib price in Malaysia (2026)
Bangladesh list prices converted into MYR, plus the registration rules of the NPRA, the legal import routes and the real cost build-up for Malaysia.
Quick answer: crizotinib price in Malaysia
Bangladeshi list price for generic crizotinib250 mg is BDT 350–BDT 1,500 per unit (about MYR 11.62–MYR 49.81), i.e. MYR 348.66–MYR 1,494 per 30-unit month; add freight, duty and distributor margin for $Malaysia.
FX basis: 1 USD = 122.87 BDT (September 2026). Conversions are indicative only — the binding price is your supplier quotation.
Currency conversion
| Item | BDT | MYR | USD |
|---|---|---|---|
| Lowest unit price | BDT 350 | MYR 11.62 | US$2.85 |
| Highest unit price | BDT 1,500 | MYR 49.81 | US$12.21 |
| 30-unit month (lowest) | BDT 10,500 | MYR 348.66 | US$85.46 |
| 30-unit month (highest) | BDT 45,000 | MYR 1,494 | US$366.24 |
Bangladesh benchmark (world reference price)
Registered brands and list prices for this molecule in Bangladesh (DGDA registration, via MedEx).
| Brand | Manufacturer | Strength | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Alkixen Lowest | Everest Pharmaceuticals Ltd. | 250 mg Capsule | BDT 350 | US$2.85 | 1 x 30: ৳ 10,500.00 |
| Algrofin | Genvio Pharma Ltd. | 250 mg Capsule | BDT 750 | US$6.10 | 7 x 4: ৳ 21,000.00 |
| Alkriz | Beacon Pharmaceuticals PLC | 250 mg Capsule | BDT 750 | US$6.10 | 7 x 4: ৳ 21,000.00 |
| Crizona | Ziska Pharmaceuticals Ltd. | 250 mg Capsule | BDT 750 | US$6.10 | 3 x 10: ৳ 22,500.00 |
| Crizonil | Jenphar Bangladesh Ltd. | 250 mg Capsule | BDT 750 | US$6.10 | 1 x 30: ৳ 22,500.00 |
| Rizonib | Drug International Ltd. | 250 mg Capsule | BDT 750 | US$6.10 | 3 x 10: ৳ 22,500.00 |
| Crizocent | Incepta Pharmaceuticals Ltd. | 250 mg Capsule | BDT 1,500 | US$12.21 | 3 x 4: ৳ 18,000.00 |
Source: MedEx Bangladesh drug registry (list prices of DGDA-registered brands). Unit prices move with pack size, pharmacy and exchange rate — reference only. Original registry page
Import and regulatory notes
National Pharmaceutical Regulatory Agency (NPRA). Malaysia has one of the better-regulated generics markets in ASEAN: products must be registered with the NPRA with a valid product licence, and hospital procurement runs through government tenders. Patient-level imports of unregistered products require an NPRA import authorisation.
How to obtain it legally
- Obtain a prescription plus the diagnostic/genetic report from the treating physician (e.g. the target-mutation result).
- Confirm the exact brand and strength, and ask the supplier for the batch number, certificate of analysis (COA) and the manufacturer's GMP credentials.
- Clear the shipment through a NPRA-licensed importer or pharmacy; unregistered products go through the named-patient route.
- Check batch number, expiry and packaging on arrival, then follow the prescriber's monitoring schedule.
What adds to the price when you import
- International freight and cold chain (monoclonal antibodies and insulins need 2–8°C end-to-end).
- Customs duty and import VAT in Malaysia.
- Compliance, licensing and warehousing cost of the importer/distributor (typically 10–30%).
- Order size and pack configuration — full cases price below retail strips.
- Exchange-rate movement: this page converts at 1 USD = 122.87 BDT.
Availability in Southeast Asia
| Country | Status | Notes |
|---|---|---|
| Malaysia | Not confirmed | No NPRA approval record or price source for crizotinib was located in this search round |
Frequently asked questions
How much does crizotinib cost in Malaysia?
There is no fixed public retail price for crizotinib in Malaysia in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 350–BDT 1,500 (US$2.85–US$12.21) per unit, about MYR 11.62–MYR 49.81 in MYR per unit and MYR 348.66–MYR 1,494 per 30-unit month, before freight, customs duty and distributor margin.
Can I legally import crizotinib into Malaysia?
Yes, but only through the rules of the National Pharmaceutical Regulatory Agency (NPRA): Malaysia has one of the better-regulated generics markets in ASEAN: products must be registered with the NPRA with a valid product licence, and hospital procurement runs through government tenders. Patient-level imports of unregistered products require an NPRA import authorisation. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.
Are Bangladeshi or Indian generics of crizotinib approved in Malaysia?
We cannot confirm the registration status of every individual generic brand in Malaysia. National Pharmaceutical Regulatory Agency (NPRA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.
Why is the Bangladesh price a useful reference?
Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.
What is the availability situation for crizotinib in Malaysia?
Malaysia: Not confirmed. No NPRA approval record or price source for crizotinib was located in this search round
This molecule in other markets
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Also sourced for Malaysia
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.